Brent Saunders [Getty Photos]
June 25, 2019 06:51 AM EDTUpdated June 26, 10:32 AM
Deals

Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

John Carroll

Editor & Founder

Brent Saun­ders has found his way out of the cur­rent fix he’s in at Al­ler­gan $AGN. He’s sell­ing the com­pa­ny to Ab­b­Vie for $63 bil­lion in the lat­est ex­am­ple of the hot M&A mar­ket in bio­phar­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

Ex­clu­sive: Aviv Regev talks three years of lead­ing Genen­tech’s re­search, the fu­ture of AI, and not mak­ing No­bel ...

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

sponsored

Sol­id Tu­mors: The Next Fron­tier of Can­cer Im­muno-ther­a­py

A service from the Financial Times